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Abstract
We compared patterns of neuropsychiatric symptom across four dementia types (AD, VAD, DLB,
PDD), and two mixed groups (AD/VAD, AD/DLB) in sample of 2,963 individuals from the
National Alzheimer’s Coordinating Center Uniform Data Set between September 2005 and June
2008. We used confirmatory factor analysis to compare neuropsychiatric symptom severity ratings
made by collateral sources on the Neuropsychiatric Inventory (NPI-Q) for people with Clinical
Dementia Rating scores of 1 or higher. A three factor model of psychiatric symptoms (mood,
psychotic, and frontal) was shared across all dementia types. Between-group comparisons revealed
unique neuropsychiatric profiles by dementia type. The AD group had moderate levels of mood,
psychotic, and frontal symptoms while VAD exhibited the highest levels and PDD had the lowest
levels. DLB and the mixed dementias had more complex symptom profiles. Depressed mood was
the dominant symptom in people with mild diagnoses. Differing psychiatric symptom profiles
provide useful information regarding the non-cognitive symptoms of dementia.
Declines in memory and attention are considered hallmark symptoms of Alzheimer’s
Disease (AD), but non-cognitive symptoms such as changes in mood, personality, and other
neuropsychiatric symptoms are also prevalent1–3 especially during later stages.4–6
Epidemiologic studies of people with incident dementia universally report mood-related
symptoms7 (e.g., apathy, depression, anxiety) with psychotic features second. In specialty
clinics, patients with vascular dementia (VAD) have been reported to experience changes in
mood and personality including increased apathy and irritability.8–9 Patients with Dementia
with Lewy Bodies (DLB) often show rigidity, poor emotional control, apathy,
hallucinations, delusions, and depression.10–12 Similar symptoms are reported in
Parkinson’s disease dementia (PDD).11, 13
Although neuropsychiatric symptoms have been described within a variety of dementia
types, few studies have compared patterns of symptoms between dementia types using a
standardized instrument8–9, 14 and those have been limited in sample size and variety of
dementia diagnoses. The current study applies a factor analytic model of the
Neuropsychiatric Inventory Questionnaire (NPI-Q)15–16 to individuals with AD, VAD,
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DLB, PDD, combined diagnoses of AD and VAD (AD/VAD), and combined AD and DLB
(AD/DLB) who participated in research at one of the national Alzheimer’s Disease Centers
contributing to the National Alzheimer Coordinating Center’s (NACC). Neuropsychiatric
evaluation of dementia characterizes patterns of psychiatric symptoms and associates unique
symptom patterns with specific neuropathological processes. The diagnostic breadth of the
current sample allows us identify unique profiles of symptoms with specific dementia types,
including less prevalent or rarer dementias (e.g., DLB) and blended dementias (e.g., AD/
VAD). Previous studies have used exploratory factor analysis to investigate how the items
of the NPI questionnaire cluster together.13–14, 17–18 Others have used latent class and
mixture modeling procedures (more exploratory techniques) to identify unique patterns of
symptoms in previously unidentified groups of dementia patients.19 In contrast, we used
confirmatory factor analysis to validate the diagnostic groups (previously established by
NACC clinicians) and compare dementia types based on their factor scores. Factor scores
have the desirable property of being more sensitive symptom summary scores than
observed/raw scores.
We began with an empirically validated three-factor model of neuropsychiatric symptoms
that was established in patients with AD (mood, psychotic, and frontal symptom domains)
by Frisoni and colleagues.17 We then tested whether this model could be extended across
multiple non-AD dementia variants. Although other models of symptom clusters do exist,
13–14, 17–18 we chose the three-factor model because its aggregation of symptoms is used
most commonly in clinical practice. Our study characterizes unique patterns of
neuropsychiatric symptoms displayed in each of these dementia types or mixed-dementias.
Because this modeling procedure used a preponderant number of patients with AD, these
results should be interpreted as relative to the AD-referent group.
Method
Sample
Data from the National Alzheimer Coordinating Center’s (NACC;
http://www.alz.washington.edu/) Uniform Data Set consist of information from Alzheimer’s
Disease Centers supported by the National Institute on Aging (NIA).16 NACC data used in
the present study were collected between September 2005 and June 2008 (acquired
November 2009). This data includes demographic information (Table 1) and clinical data
collected for 2,963 individuals who had archival data for NPI-Q, and Clinical Dementia
Rating (CDR) score of 1 or higher (to ensure presence of neuropsychiatric symptoms).
Individuals met the following clinical diagnostic criteria for primary diagnosis: AD (n =
2,474), DLB (n = 151), VAD (n = 85), PDD (n = 74), AD/VAD (n=92; AD was primary
diagnosis), and AD/DLB (n = 87; AD was primary diagnosis). The AD and DLB groups
contain only persons without other concurrent diagnoses. For VAD and PDD, we used
primary diagnosis although they include cases that are not pure, i.e. they may be of mixed
diagnosis. Individuals in the AD group who were less than 60 years of age were excluded.
Sample sizes for other mixed-dementia diagnoses were too small for inclusion in these
analyses (n’s < 50).
Procedures
Individual NACC ADC studies were approved by local human subjects committees. Written
informed consent was obtained from all patients and/or collateral sources. AD diagnosis was
based on NINCDS-ADRDA.20 VAD was diagnosed according to NINDS-AIREN criteria21
DLB was diagnosed according the criteria established by the DLB Consortium.22 PDD was
diagnosed per the criteria established by the Movement Disorders Society Scientific Issues
Committee.23
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Trained clinicians administered the NPI-Q to an informant knowledgeable about the
patient’s behavior. This measure assesses 10 behavioral disturbances that may occur in
dementia and other neuropsychiatric disorders: delusions, hallucinations, dysphoria, anxiety,
agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor
activity. We combined the presence and severity questions for each NPI-Q item. Thus,
symptom severity was rescaled from 0 to 3, and treated as a ratio scaled index of the
assessed symptom, 0 indicating no symptom present and 3 indicating severe
symptomatology.
Statistical Analyses
Confirmatory Factor Analysis (CFA) with full information maximum likelihood was
conducted in a multi-step process.24 Step 1: to assess the relative fit of a 3-factor baseline
model of psychiatric features in AD developed by Frisoni et al. 17, we collapsed across all
dementia participants (n= 2,963) and examined domain content, factor loadings, and factor
interrelationships (Figure 1). The three factors specified in this model are Mood (indicated
by anxiety, apathy, and dysphoria items), Psychosis (irritability/lability, delusions,
hallucinations, and agitation/aggression), and Frontal symptoms (euphoria and
disinhibition). Step 2: The baseline model was used in a series of increasingly restrictive
between group tests of invariance (TOI) comparing 4 types of dementia (AD, VAD, DLB,
PDD) and 2 groups of mixed dementia (AD/VAD, and AD/DLB).Less constrained models
must be accepted before subsequent higher order solutions can be interpreted. These tests
indicate whether the psychometric properties of the instrument (factor structure and
variance-covariance patterns) differ between the samples. The test of weak invariance is the
least restrictive. Good fit indicates that the groups share the same factor structure and the
same factor loadings. The test of strong invariance requires all assumptions for weak as well
as the same test item intercepts across groups. No differences at strong invariance (equal
factor loadings and item intercepts) indicate that the groups share similar psychometric
configurations for the NPI-Q. Differences at strong invariance indicate the groups differ in
the amount of the trait measured. This provides the analytic reasoning for Step 3, a between
group comparison on latent means using a test of latent mean invariance. Failure of a test of
latent mean invariance suggests that groups differ in their mean levels of mood, psychotic,
and frontal symptoms. Step 4: If step 3 fails to fit, we estimate how much these groups
differ by constraining as many between group coefficients to be equal as theoretically
feasible and statistically warranted (model optimization). This yields a parsimonious model
of between group similarity and difference.25 To evaluate model changes at each step of the
analyses, we used goodness-of-fit indices as prescribed by Cheung & Rensvold.26 In the
first 2 steps, the psychometric properties of the model were evaluated using change in the
Root Mean Square Error of Approximation (ΔRMSEA < − .02). In the final 2 steps




Dementia severity (CDR) did not differ between the groups (F = 1.11, p = .35; note all
participants CDR ≥ 1). Omnibus tests for group differences in Age, Gender, and Education
were all significant (all F’s > 4.58, p < .001). Bonferroni corrected pairwise comparisons
revealed that the PDD and DLB groups were younger than all other groups (p<.001) and
contained far fewer women (Χ2 (5) = 107.5, p < .001); however, all other group
comparisons were nonsignificant. Importantly, AD participants were statistically equivalent
to all other dementia groups on Age, Gender, and Education and thus were not controlled for
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in the modeling process. There was modest variation in level of education across the groups
(Range 12.4 to 14.7), but only the two most extreme groups differed significantly (VAD vs.
PDD).
Because dementia severity (CDR) affected symptom presentation (Table 2), all models
reported here are adjusted for CDR status. Participants with more progressed AD reported
more psychotic symptoms (β = .23, p < .001) and more frontal symptoms (β = .10, p < .01).
For DLB, higher dementia severity predicted an increase in psychotic symptoms (β = .30, p
< .01). For AD/VAD, higher dementia severity predicted increased mood symptoms (β = .
42, p < .05) and psychotic symptoms (β = .55, p < .001). For AD/DLB, higher dementia
severity predicted increased frontal symptoms (β = .42, p < .05). Disease severity did not
predict the levels of any type of symptoms on the NPI in the PDD or VAD groups.
Step 1—We examined domain content, factor loadings, and factor interrelationships of the
three factor model originally proposed by Frisoni and colleagues (Figure 1).17 The best
fitting model was both similar to and different from the Frisoni model. Like Frisoni, we
found that the aberrant motor activity item loaded highly on all three factors (betas ranged
from 0.34 to 0.51) and resulted increased model misfit (Δ RMSEA = +.01). Thus, it was
excluded from the baseline model. Unlike Frisoni, we found that the apathy item fit well in
the baseline, thus it was included. Finally, delusions and hallucinations items covaried
significantly (Δ RMSEA < −.02).
Step 2—Multiple-group TOI’s were used to compare the different types of dementia (Table
3). The tests of weak invariance (equivalent factor loadings) and strong invariance
(equivalent factor loadings and item intercepts) indicated that the groups were statistically
equivalent at these levels (neither Δ RMSEA > −.02).
Step 3—The test for equal latent means failed (Δχ2(15) = 79.0, p<.001) indicating that
although the groups shared the same model configuration (3 latent domains made up by
Mood, Psychosis, and Frontal symptom clusters), neuropsychiatric profiles varied by
dementia type (Table 2). Compared to the other four patient groups, AD participants scored
in the moderate range across the symptom domains (Mood = .78, Psychosis = .52, and
Frontal = .25). Patients with VAD reported the highest symptom levels (Mood = .90,
Psychosis = .60, and Frontal = .36) and PDD reported the lowest (Mood = .67, Psychosis = .
46, and Frontal = .11).
Step 4—In the final optimized model (Figure 2), diagnoses clustered in two levels on the
Mood symptom domain (VAD = AD/DLB = DLB > AD =AD/VAD = PDD), in three levels
on the Psychosis symptom domain (VAD > AD = AD/DLB = DLB > AD/VAD = PDD),
and in three levels on the Frontal symptom domain (VAD > AD/VAD = AD = AD/DLB =
DLB > PDD). Notably DLB and AD/DLB had identical patterns of factor means across all
domains. AD/VAD had an identical pattern to AD on Mood and Frontal symptoms, but AD/
VAD was lower than AD on Psychosis. Dementia types also shared similar correlation
structures (Table 2) between Mood and Frontal symptoms (r = .38) and between Psychotic
and Frontal symptoms (r = .52). Thus the groups shared similar relationships among the
least frequently occurring neuropsychiatric symptoms. The dementia types did differ
significantly in how Mood and Psychotic symptoms correlated. In AD they correlated in the
moderate range (r = .62) and could not be not equated to any of the other diagnosis groups.
In the two mixed diagnoses and in DLB correlations were higher (r = .80). Finally, VAD and
PDD shared similar low correlations (r = .32).
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Using a large sample of mild to moderate staged people with dementia from the NACC
database, this study compared the neuropsychiatric profiles of 4 common dementia types
(AD, VAD, DLB, PDD) and 2 mixed dementias (AD/VAD and AD/DLB). We found that
dementia types shared many common symptoms and could be compared to one another
along three psychiatric symptom domains (Mood, Psychosis, and Frontal). The group
profiles differed in the severity and inter-relatedness of the symptom domains. Participants
with AD consistently reported moderate symptom severities, VAD the highest, and PDD the
lowest (probably due to their younger age and relative milder stage of disease). DLB and the
mixed dementias reported more complex symptom profiles. Given that these DLB patients
probably have concomitant AD-type changes it appears the multiple co-occurring
neuropathologies are interactive in some way, resulting in more extensive psychiatric
symptom complexes.
Across dementia types, caregivers reported that the person with dementia experienced
psychiatric symptoms like Anxiety, Dysphoria, and Apathy (items that make up the Mood
symptom domain) more frequently than symptoms like Irritability, Delusions,
Hallucinations, and Agitation (Psychosis symptom domain). Note that visual hallucinations
are part of the diagnostic criteria for DLB and were expected to be higher in this group.
Euphoria and Disinhibition (Frontal symptom domain) were the least likely to be endorsed.
These data indicate a consistent neuropsychiatric symptom profile (Mood > Psychosis >
Frontal) across dementia types wherein depressed mood is a prominent feature in all.1–2, 7–
9, 11, 13 Although each disease is the result of different underlying pathologies (or blends of
pathologic processes), they all reflect the presence of major neurologic disease resulting in
extensive cell death and brain atrophy. The trauma associated with these processes appears
to yield a depressive tone similar to what is witnessed in post-ictal stroke patients and other
brain trauma.27 This is likely why the VAD and AD/VAD blend report such high rates of
mood symptoms.
Lower levels of endorsement of Psychosis and Frontal symptom domains is likely due to the
mild and moderate stages of dementia patients tested. In this sample, people in the later
stages of dementia reported more of the symptoms that make up the Frontal and Psychosis
domains; increasing dementia severity (CDR) was related to more severe Frontal symptoms
(AD) and more Psychosis symptoms in AD, DLB, AD/DLB, and AD/VAD. Dementia status
(CDR) did not correlate with symptom severity in PDD and VAD. The PDD group did not
have as many later stage individuals, were slightly younger, and did not suffer as many
neuropsychiatric symptoms. This may have attenuated the correlations of disease severity
with neuropsychiatric symptoms in the PDD group. There were adequate numbers of later
stage VAD participants and this group endorsed the greatest symptom severity. Thus,
dementia severity (CDR) had less impact on symptom presentation in VAD.
Profiles of the mixed dementias indicated that when AD is concomitant with VAD, the AD-
like psychiatric features tend to dominate but that when AD is concomitant with DLB, DLB-
like psychiatric features tend to dominate. Across the 3 domains measured, AD/VAD
participants reported less severe symptoms than VAD alone and this was similar to AD
participant reports. The profile differences between VAD and AD/VAD may account for
mixed reports of symptoms in the literature, some reporting more severe depression &
anxiety,9, 28 others reporting equivalent symptoms in AD and VAD.29 Both sets of
observations may both be true depending on the makeup of the patient group studied. DLB
and AD/DLB had identical patterns of factor means, most starkly characterized by high
levels of mood symptoms. The presence of simultaneous AD and DLB pathology may
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represent an additive effect where the two diseases together result in more significant
manifestation of mood symptoms.30 This is consistent with research reports that patients
with DLB often experience apathy and depression.11–12
NACC participants are recruited and enrolled in a variety of ways across participating
ADCs, thus this large dataset likely suffers from diagnostic inconsistencies. Specifically,
NACC is a clinic-based convenience sample and its generalizability may be limited. This
clinic-based sample likely overestimates true prevalence of AD in the geriatric population.
Participating ADCs focus on AD diagnosis and recruitment, thus biasing the sample toward
over inclusion of AD variants. For example, the PDD participants reported mild psychiatric
symptoms given their dementia status. These participants differ from previous reports about
the NPI-Q used in PDD.13 Differences in when and how these participants present for
evaluation may explain why this PDD group was unexpectedly low in reporting psychiatric
symptoms. As a result, these PDD data may not generalize well to movement disorder
clinics. Others have noted that caregivers’ appreciation of psychiatric symptoms may
outstrip their ability to judge accurately symptom presence and severity, resulting in
relatively higher levels of variability witnessed in these types of data.31 In spite of these
modest limitations the results of this study show that the NPI-Q can be used effectively to
assess many types of dementia, their neuropsychiatric symptom profiles have unique
features, and these results are consistent with several other studies.2, 11, 13, 32–33
Although AD was over-represented in these data because it is the most prevalent dementia
type worldwide and the primary target of NACC participating ADC’s, this pattern of results
is not dependent on the large AD sample size. When analyses were repeated with a
randomly selected AD subsample (N = 300) and tested using bootstrapped confidence
intervals, results were identical. Further, the other dementias reported here are of great
clinical value because of their relative rarity and that they were tested with a standardized
battery. Due to the large sample size of the NACC database, the present study offers unique
advantages because it aggregates relatively understudied dementias. Thus, we could
demonstrate that the Frisoni and colleagues’ 3-factor model of the NPI-Q can be applied in a
wide range of geriatric clinical settings to investigate patterns of neuropsychiatric symptom
severity across many dementia types.
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Caption: Accepted Baseline Three-Factor Model of Neuropsychiatric Symptoms on the NPI-
Q. Adjustment for CDR as a covariate is not represented in the figure.
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Clinical Profiles by Dementia Type: Optimized Factor Means on NPI-Q
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